Overview of management procedures of hepatic encephalopathy

Abdullah Mosfer Alelyani, Awad Salem Alrashdi, Ibrahim Abdullah Homadi, Mohammed Ahmed Aleissa, Osama Zaid Fatani, Rawan Jamil Jarwan, Rakan Yousef Alqarni, Sami ailan Alahmry

Abstract:

The aim of this review is to summarize the current knowledge related to the pathogenesis leading to HE, as well as the subsequent therapeutic and diagnosis options. Detailed search was conducted throughout the electronic databases; PubMed, and Embase, for relevant studies discussing the management procedures of hepatic encephalopathy. Hepatic encephalopathy is an essential complication of liver cirrhosis connected with morbidity and mortality. Hepatic encephalopathy is also related to considerable health care utilization and damaging impact of care givers. Early acknowledgment of HE is important for timely management. Treatment of HE revolves around its seriousness and consists of lactulose and rifaximin either alone or in combination. Nutritional change may also enhance HE recurrence. Investigation is still ongoing regarding options for managing clinically refractory HE including spontaneous splenorenal shunt embolization, glycerol phenyl-butyrate, and artificial liver support.Cirrhosis and its problems stay a major burden on the health care systems worldwide. Despite extensive research study and clinical tests, the pathogenesis of HE stays to be further elucidated and more efficient treatments are needed.

Introduction:

Hepatic encephalopathy (HE) is characterized by reversible neurologic and psychological irregularities in attentiveness, cognition, sleep, coordination, extrapyramidal function, mood, or behavior. Hepatic encephalopathy could occur in the context of acute liver failure, portal-systemic bypass without hepatocellular disease, and in cirrhosis and portal hypertension [1].HE is usually identified as overt (with obvious symptoms) or minimal (subtle symptoms considerable on neuropsychiatric screening) and more defined as episodic, recurring (more than one episode within 6 months), or consistent. Though HE is typically broken down right into five grades,there is a range of neurocognitive disability varying from light psychometric deficits to obvious coma [2].Overt HE occurs in 30 % 45 % of cirrhotics and 10 % 50 % of those with transjugular intrahepatic portal-systemic shunts [3], [4].Minimal HE, defined by deficits in temporary memory, interest and exec function, happens in as much as 84 % of patients with cirrhosis and is normally found by detailed neuropsychiatric batteries [5].

The aim of this review is to summarize the current knowledge related to the pathogenesis leading to HE, as well as the subsequent therapeutic and diagnosis options.

Methodology:

Detailed search was conducted throughout the electronic databases; PubMed, and Embase, for relevant studies discussing the management procedures of hepatic encephalopathy. Studies which are published up to October, 2017 with English language and human subjects were included. Furthermore, references found in included studies scanned for more relevant articles to be included in our review.

Discussion:

- **PATHOGENESIS**

The liver has a central detoxifying function in the body with its capability of neutralizing many toxic chemicals taken in from the gastrointestinal (GI) system and others produced as byproducts of typical metabolism. The majority of these toxins get to the liver through the portal venous system and experiencing the low flow hepatic sinusoids these substances are effectively caught and detoxed by hepatocytes. With the progression of liver fibrosis and advancement of cirrhosis the enhanced hepatic resistance requires the blood to bypass the liver by flowing via portosystemic shunts. This results in pooling of numerous toxins right into the systemic circulation and at some point reaching the brain and other organs. Along with these hemodynamic modifications, the efficient hepatocyte mass is considerably lowered in cirrhosis, therefore it can be conveniently overwhelmed by relatively small amounts of toxins [6].

Normal mind function requires physiological brain integrity, enough energy manufacturing, and reliable synapse neurotransmission, all of which are impaired in HE. Although the system of this problems is not extremely clear, numerous aspects and pathways communicate together causing the central nerve system (CNS) dysfunction which manifests clinically as varying levels of HE [7].

- **DIAGNOSIS**

The medical diagnosis of HE is based upon the presence of a spectrum of neuropsychiatric abnormalities in patients with liver dysfunction after exclusion of unrelated neurologic and/or metabolic causes of encephalopathy. The procedure of exclusion of various other causes of encephalopathy may demand obtaining different laboratory and imaging modalities consisting of computer tomography (CT), magnetic resonance imaging (MRI), electroencephalography (EEG),

and others [8].Laboratory abnormalities in patients with HE consist of those that suggest serious liver illness such as raised bilirubin, alanine aminotransferese (ALT) and aspartate aminotransferese (AST), alkaline phosphatase, international normalized ratio (INR), decreased serum albumin degree, in addition to possible electrolyte disruptions related to portal hypertension or the use of diuretics.

Serum and arterial ammonia levels are typically elevated in patients with HE, yet the utility of these examinations is controversial because of the fact that these levels are substantially impacted by collection methods and can be falsely raised if the sample was gathered after fist clenching, utilizing tourniquet, or if the sample was not placed on ice [9].

A number of specialized psychometric and neuropsychiatric examinations with a high capability of finding minor shortages in mental function are readily available for the diagnosis and characterization of HE [13].Nonetheless, as these tests are labor and time consuming and their reliability is decreased by the understanding effect with repetitive administration, they are typically utilized for research purposes [10] In addition, a general trouble with psychometric tests is that they are not specific to HE and various other forms of encephalopathy such as when it comes to chronic alcoholism, Wilson illness, and potentially chronic hepatitis C infection can show similar results and findings [14].

One of the most regularly used examination is the number connection test (NCT). Additionally, a battery of five paper-pencil tests were incorporated together to develop the Psychometric Hepatic Encephalopathy Score (PHES) which can evaluating visual perception, visuo-spatial alignment, visual building, motor rate and precision, focus, focus, and memory. The PHES includes the line tracing examination, number symbol examination, serial dotting test, and the NCT A and B, and can be performed at bedside [12].

Other tests made use of in the diagnosis of HE include the inhibitory control test (ICT) which is a computerized test of interest and reaction restraint. This test was originally developed to evaluate patients with attention deficit disorder, schizophrenia, and stressful brain injury. Another test also generally made use of in the diagnosis of MHE is the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) [11].

Strategies that tape-record the evoked capacities from neuronal networks have been made use of to show synchronous volleys of discharges in response to numerous sensory stimuli. Essential flicker frequency test can be used to examine for hepatic retinopathy as a reflection of encephalopathy, as retinal glial cells are likewise associated with ammonia detoxification by glutamine synthesis and display morphological modifications just like those observed in brain astrocytes [11].

A crucial repercussion of the application of psychometric tests in patients with cirrhosis was the searching for that a substantial portion of patients with evidently typical psychological standing have a measurable deficiency in their intellectual performance, lasting memory, and discovering capability. This subclinical or very little HE impacts up to 80 percent of patients with cirrhosis and this problem typically fixes complying with liver transplantation [12].

- **TREATMENT**

Nutrition

Maintaining appropriate nutrition is essential in patients with HE. Protein calorie malnutrition is commonly found in HE patients and has been connected with poor prognosis. Frequently inappropriate recommendations to reduce protein consumption, constant body liquid elimination using paracentesis or anemia from intestinal hemorrhaging all most likely add [15].Maintaining

appropriate protein intake is crucial in stopping muscular tissue losing. After the liver, skeletal muscle is the largest site of ammonia metabolic process [16].Just like astrocytes, skeletal muscle mass utilize glutamine synthetase to generate glutamine from ammonia and glutamate. The glutamate is in turn synthetized from branch chain amino acids. This paths is most likely the reason HE patients have been recorded to have lower focus of lotion branch chained amino acids. Current studies offer proof for the advantages of protein intake with every meal as well as late evening treats to avoid protein breakdown over night [17].Gluud et al. [18] conducted a meta-analysis of 8 trials assessing the results of oral BCAAs in HE and concluded that oral branch chain amino acids boosted manifestations of HE however no impact on overall death or nutrition status was observed.

An expert panel commissioned by the ISHEN have given detailed recommendations on nutritional management of patients with hepatic enceophalopathy [19].The board ended that optimal everyday power consumption must be 35 to 40 kcal/kg ideal body weight with everyday protein consumption of 1.2 to 1.5 g/kg optimal body weight and fiber intake of 25 to 45 g daily. Additionally meals should little and evenly distributed throughout the day with a late night snack of complicated carbohydrates to decrease protein usage over night. Patients need to be encouraged to follow diets rich in vegetable and dairy protein. If patients are intolerant of dietary protein, BCAA supplementation is an alternative to consider. Multivitamin use can be considered in patients confessed for decompensated cirrhosis with the addition of particular treatments for clinically apparent vitamin deficiencies.

Nonabsorbable disaccharides

Nonabsorbable disaccharides, lactulose and lactitol, have long been the mainstay of treatment for HE. Guidelines from both the American Association for the Study of Liver Disease (AASLD) and European Association for the Study of Liver Disease both recommend the use of these representatives. Although nonabsorbable disaccharides are the most typically prescribed medication for HE, a Cochrane review discovered no statistically considerable impact on mortality when comparing placebo or no treatment to nonabsorbable disaccharides [20].Moreover there was no statistically significant distinction between lactulose and lactitol on mortality. Nonabsorbable disaccharides had an enhanced danger of no improvement when as compared to antibiotics. Sharma et al. [21] performed an empirical research of 231 patients confessed for HE diagnosed by West Haven Criteria and found that 78% replied to lactulose within 10 days of admission. Feedback was defined as no longer meeting standards for HE. Multivariate analysis of baseline characteristics discovered that overall leukocyte count, MELD mean arterial pressure and hepatocellular carcinoma were independent predictors of nonresponse to lactulose. Appropriate dosing is crucial in the effective management of HE. One study showed that nearly 50% of HE recurrence were related to either no adherence or inappropriate dosing [22].Numerous elements add to this lack of appropriate adherence.Several research studies have shown benefit in primary prophylaxis with lactulose in patients that have never had an episode of HE Bajaj et al. [24] showed that treating very little hepatic with lactulose was cost effective in preventing motor vehicle crashes. An open label, randomized control test evaluating using lactulose in cirrhotic patient who have never had an episode of OHE discovered that, over the 12 months of follow-up, 11% of patients in the lactulose team established signs and symptoms of OHE compared with 28% in the team that did not obtain lactulose [23]. Present guidelines nevertheless do not recommend the routine use of lactulose for primary prophylaxis in HE.

Antibiotics

Neomycin, vancomycin and metronidazole have been traditionally utilized in the setting of HE. Nonetheless rifaximin has become the antibiotic of selection in the treatment of HE because of its security, efficiency and tolerability. Furthermore rifaximin is nonabsorbable permitting it to concentrate in the gut and restrict its systemic absorption. A double-blind, randomized, placebo-controlled test entailing 299 patients in remission from HE found that rifaximin was extra effective than placebo in avoiding advancement HE [25].Patients on rifaximin had actually a lowered threat of an episode of HE as compared to the placebo team with a breakthrough rate of 22.1% compared to 45.9% in the placebo group, HR of 0.42 (95% CI, 0.28 to 0.64; $p<0.001$). Additionally patients in the rifaximin team had a HE related a hospital stay rate of 13.6% as compared with 22.6% in the placebo group, a Human Resources of 0.5 (95% CI, 0.29 to 0.87; $p=0.01$). The research additionally assessed the safety and security and tolerability of continuous rifaximin used for 24 months and discovered no increase in adverse occasions, infection with Clostridium difficile or development of bacterial antibiotic resistance [26].Existing guidelines from AASLD suggest lactulose as first treatment for HE, however rifaximin monotherapy has been shown to be effective [27].In addition while mix therapy for low quality HE has not been shown to improve end results, mix treatment must be thought about for reoccurring HE on lactulose or severe HE.

When compared with neomycin, rifaximin was to be a minimum of as efficient in reducing blood ammonia degrees and had much less negative results [29].In addition rifaximin has been shown to be noninferior to lactulose [30].Combination treatment with rifaximin and lactulose is likely more useful compared to lactulose alone. Sharma et al. performed a randomized, double-blind,

placebo-controlled test assessing lactulose plus rifaximin compared to lactulose alone and showed that mix therapy was indeed extra effective. Of the patients treated with mix treatment, 76% had full reversal of HE as compared to 50.8% in the lactulose just team. Moreover there was significant renovations in mortality and hospital remain in the mix group.

Neomycin has been formerly used extensively in the management of HE. It has been revealed to decrease the intestinal manufacturing of ammonia from glutamine and likely work as a glutaminase prevention. Nonetheless adverse results such as ototoxicity and nephrotoxicity restricts its use in clinical technique [28].Similarly, metronidazole is not currently suggested due to concern of nephrotoxicity and neurotoxicity with long-term use. Furthermore vancomycin is nephrotoxic and considerable usage increases the threat of kidney injury in addition to advancement of resistance [28].

Probiotics

As gut bacteria play a central role in generating ammonia it has been theorized that altering gut flora utilizing probiotics could be beneficial in HE. A number of randomized control tests have been carried out contrasting probiotics to sugar pill or no treatment in addition to lactulose and have revealed some benefit. The use of probiotics in secondary treatment was examined in an open-label, randomized regulated trial involving 235 patients divided right into a lactulose, probiotic or no treatment arm [31].Reappearance rate was located to be 26.2% (18 of 68) in the lactulose arm, 34.4% (22 of 64) in the probiotic arm and 56.9% (37 of 68) in the no therapy arm. While both lactulose and probiotics were dramatically more effective than no treatment, no significant distinction was found in between both. Zhao et al. [32] just recently conducted a

systemic evaluation of 9 randomized control trials and concluded that probiotics were connected with renovation in MHE, prophylaxis of OHE and reduction in serious adverse occasions.

Polyethylene glycol

Prior to the widespread adoption of nonabsorbable disaccharides, straightforward laxatives were frequently used to treat HE with some benefit recommending that digestive tract evacuation alone could efficiently treat HE [33].Polyethylene glycol is a commonly utilized, safe and very reliable laxative that has lately been recommended as a possible representative for HE. Rahimi et al. [34] compared using polyethylene glycol 3350-electrolyte remedy versus lactulose in the therapy in 50 patients with underlying cirrhosis admitted for HE. Primary endpoint gauged was renovation of HE quality by 1 or even more points determined by the HE racking up algorithm. Of the patients that received polyethylene glycol, 21 of 23 (91%) had an enhancement in HE as compared to 13 of 25 (52%) in the lactulose arm, a significant difference ($p<0.01$). Furthermore the median time for HE resolution in the polyethylene glycol group was 1 day as compared to 2 days in the conventional therapy arm ($p=0.01$).

Flumazenil

Flumazenil is a benzodiazepine antagonist that targets GABA receptors. Laccetti et al. [35] performed a double blind randomized, placebo regulated test assessing using flumazenil in acute HE. Of the patients that were treated with flumazenil 79% (22 of 28) showed clinical renovation compared with 54% (14 of 26) in the placebo arm. No mortality benefit was observed.

Ammonia scavengers

Ammonia scavengers help to enhance ammonia clearance and thus reduce systemic concentrations of ammonia. Glycerol phenylbutyrate lowers serum ammonia by giving an alternative pathway for renal clearance of nitrogen through phenylacetyl-glutamine. A recent stage II clinical trial showed that glycerol phenylbutyrate lowered HE events (21% vs 36% in placebo team, p=0.02), was associated with fewer HE hospital stays and reduced plasma ammonia [36].In subgroup analysis of patients taking lactulose at standard, the glycerol phenylbutyrate team had a HE occasion rate of 22% versus 45% in the placebo team ($p<0.01$). However there was no difference between treatment arms in those patients taking rifaximin at baseline. Ornithine pheynlacetate is another ammonia scavenger that increases the exact same pathway as glycerol phenylbutyrate, resulting in discharging of ammonia in urine as pheynylacetylglutamine. Ornithine phenylacetate has been revealed to lower plasma ammonia levels in patients with decompensated cirrhosis [37].Ornithine and aspartate are substrates of the urea cycle.

Conclusion:

Hepatic encephalopathy is an essential complication of liver cirrhosis connected with morbidity and mortality. Hepatic encephalopathy is also related to considerable health care utilization and damaging impact of care givers. Early acknowledgment of HE is important for timely management. Treatment of HE revolves around its seriousness and consists of lactulose and rifaximin either alone or in combination. Nutritional change may also enhance HE recurrence. Investigation is still ongoing regarding options for managing clinically refractory HE including spontaneous splenorenal shunt embolization, glycerol phenyl-butyrate, and artificial liver support.Cirrhosis and its problems stay a major burden on the health care systems worldwide.

Despite extensive research study and clinical tests, the pathogenesis of HE stays to be further elucidated and more efficient treatments are needed.

Reference:

1. Ferenci P, Lockwood A, Mullen K, Tarter R, Weissenborn K, Blei AT. Hepatic encephalopathy–definition, nomenclature, diagnosis, and quantification: final report of the working party at the 11th World Congresses of Gastroenterology, Vienna, 1998. Hepatology. 2002;35(3):716– 21.
2. Bajaj JS, Wade JB, Sanyal AJ. Spectrum of neurocognitive impairment in cirrhosis: implications for the assessment of hepatic encephalopathy. Hepatology. 2009;50(6):2014–21.
3. Romero-Gomez M, Boza F, Garcia-Valdecasas MS, Garcia E, Aguilar-Reina J. Subclinical hepatic encephalopathy predicts the development of overt hepatic encephalopathy. Am J Gastroenterol. 2001;96(9):2718–23.
4. Boyer TD, Haskal ZJ. American association for the study of liver D. The role of transjugular intrahepatic portosystemic shunt in the management of portal hypertension. Hepatology. 2005;41(2):386–400.
5. Wang JY, Zhang NP, Chi BR, Mi YQ, Meng LN, Liu YD, et al. Prevalence of minimal hepatic encepha297, Page 32 of 37 Curr Treat Options Neurol (2014) 16:297 lopathy and quality of life evaluations in hospitalized cirrhotic patients in China. World J Gastroenterol. 2013;19(30):4984–91.
6. Blauenfeldt RA, Olesen SS, Hansen JB, Graversen C, Drewes AM. Abnormal brain processing in hepatic encephalopathy: Evidence of cerebral reorganization? Eur J Gastroenterol Hepatol. 2010;22:1323–30.
7. Wright G, Noiret L, Olde Damink SW, Jalan R. Interorgan ammonia metabolism in liver failure: The basis of current and future therapies. Liver Int. 2011;31:163–75.
8. Sanyal AJ, Mullen KD, Bass NM. The treatment of hepatic encephalopathy in the cirrhotic patient. Gastroenterol Hepatol (N Y) 2010;6(4 Suppl 8):1–12.
9. Bismuth M, Funakoshi N, Cadranel JF, Blanc P. Hepatic encephalopathy: From pathophysiology to therapeutic management. Eur J Gastroenterol Hepatol. 2011;23:8–22.
10. Butterworth RF. Editorial: Rifaximin and minimal hepatic encephalopathy. Am J Gastroenterol. 2011;106:317–8.
11. Blauenfeldt RA, Olesen SS, Hansen JB, Graversen C, Drewes AM. Abnormal brain processing in hepatic encephalopathy: Evidence of cerebral reorganization? Eur J Gastroenterol Hepatol. 2010;22:1323–30.

12. Reddy PV, Rama Rao KV, Norenberg MD. Inhibitors of the mitochondrial permeability transition reduce ammonia-induced cell swelling in cultured astrocytes. J Neurosci Res. 2009;87:2677–85.
13. Sharma P, Agrawal A, Sharma BC, Sarin SK. Prophylaxis of hepatic encephalopathy in acute variceal bleed: A randomized controlled trial of lactulose versus no lactulose. J Gastroenterol Hepatol. 2011;26:996–1003.
14. Blei AT, Cordoba J. Hepatic Encephalopathy. Am J Gastroenterol. 2001;96:1968–76.
15. Bémeur C, Desjardins P, Butterworth RF. Role of nutrition in the management of hepatic encephalopathy in end-stage liver failure. J Nutr Metab. 2010;2010:489823. doi: 10.1155/2010/489823.
16. Holecek M. Branched-chain amino acids and ammonia metabolism in liver disease: therapeutic implications. Nutrition. 2013;29:1186–1191. doi: 10.1016/j.nut.2013.01.022.
17. Holecek M. Ammonia and amino acid profiles in liver cirrhosis: effects of variables leading to hepatic encephalopathy. Nutrition. 2015;31:14–20. doi: 10.1016/j.nut.2014.03.016.
18. Gluud LL, Dam G, Borre M, et al. Oral branched-chain amino acids have a beneficial effect on manifestations of hepatic encephalopathy in a systematic review with meta-analyses of randomized controlled trials. J Nutr. 2013;143:1263–1268. doi: 10.3945/jn.113.174375.
19. Amodio P, Bemeur C, Butterworth R, et al. The nutritional management of hepatic encephalopathy in patients with cirrhosis: International Society for Hepatic Encephalopathy and Nitrogen Metabolism Consensus. Hepatology. 2013;58:325–336. doi: 10.1002/hep.26370.
20. Als-Nielsen B, Gluud LL, Gluud C. Nonabsorbable disaccharides for hepatic encephalopathy. Cochrane Database Syst Rev. 2004;2:CD003044.
21. Sharma P, Sharma BC, Sarin SK. Predictors of nonresponse to lactulose in patients with cirrhosis and hepatic encephalopathy. Eur J Gastroenterol Hepatol. 2010;22:526–531. doi: 10.1097/MEG.0b013e3283341b7d.
22. Bajaj JS, Sanyal AJ, Bell D, Gilles H, Heuman DM. Predictors of the recurrence of hepatic encephalopathy in lactulose-treated patients. Aliment Pharmacol Ther. 2010;31:1012–1017.
23. Sharma P, Sharma BC, Agrawal A, Sarin SK. Primary prophylaxis of overt hepatic encephalopathy in patients with cirrhosis: an open labeled randomized controlled trial of lactulose versus no lactulose. J Gastroenterol Hepatol. 2012;27:1329–1335. doi: 10.1111/j.1440-1746.2012.07186.x.
24. Bajaj JS, Pinkerton SD, Sanyal AJ, Heuman DM. Diagnosis and treatment of minimal hepatic encephalopathy to prevent motor vehicle accidents: a cost-effectiveness analysis. Hepatology. 2012;55:1164–1171. doi: 10.1002/hep.25507.
25. Bass NM, Mullen KD, Sanyal A, et al. Rifaximin treatment in hepatic encephalopathy. N Engl J Med. 2010;362:1071–1081. doi: 10.1056/NEJMoa0907893.

26. Mullen KD, Sanyal AJ, Bass NM, et al. Rifaximin is safe and well tolerated for long-term maintenance of remission from overt hepatic encephalopathy. Clin Gastroenterol Hepatol. 2014;12:1390–1397.e2. doi: 10.1016/j.cgh.2013.12.021.
27. Neff GW, Jones M, Broda T, et al. Durability of rifaximin response in hepatic encephalopathy. J Clin Gastroenterol. 2012;46:168–171. doi: 10.1097/MCG.0b013e318231faae.
28. Leise MD, Poterucha JJ, Kamath PS, Kim WR. Management of hepatic encephalopathy in the hospital. Mayo Clin Proc. 2014;89:241–253. doi: 10.1016/j.mayocp.2013.11.009.
29. Pedretti G, Calzetti C, Missale G, Fiaccadori F. Rifaximin versus neomycin on hyperammoniemia in chronic portal systemic encephalopathy of cirrhotics: a double-blind, randomized trial. Ital J Gastroenterol. 1991;23:175–178.
30. Jiang Q, Jiang XH, Zheng MH, Jiang LM, Chen YP, Wang L. Rifaximin versus nonabsorbable disaccharides in the management of hepatic encephalopathy: a meta-analysis. Eur J Gastroenterol Hepatol. 2008;20:1064–1070. doi: 10.1097/MEG.0b013e328302f470.
31. Agrawal A, Sharma BC, Sharma P, Sarin SK. Secondary prophylaxis of hepatic encephalopathy in cirrhosis: an open-label, randomized controlled trial of lactulose, probiotics, and no therapy. Am J Gastroenterol. 2012;107:1043–1050. doi: 10.1038/ajg.2012.113.
32. Zhao LN, Yu T, Lan SY, et al. Probiotics can improve the clinical outcomes of hepatic encephalopathy: an update meta-analysis. Clin Res Hepatol Gastroenterol. 2015;39:674–682. doi: 10.1016/j.clinre.2015.03.008.
33. Manning RT, Delp M. Management of hepatocerebral intoxication. N Engl J Med. 1958;258:55–62. doi: 10.1056/NEJM195801092580201.
34. Rahimi RS, Singal AG, Cuthbert JA, Rockey DC. Lactulose vs polyethylene glycol 3350: electrolyte solution for treatment of overt hepatic encephalopathy. The HELP randomized clinical trial. JAMA Intern Med. 2014;174:1727–1733. doi: 10.1001/jamainternmed.2014.4746.
35. Laccetti M, Manes G, Uomo G, Lioniello M, Rabitti PG, Balzano A. Flumazenil in the treatment of acute hepatic encephalopathy in cirrhotic patients: a double blind randomized placebo controlled study. Dig Liver Dis. 2000;32:335–338. doi: 10.1016/S1590-8658(00)80027-4.
36. Rockey DC, Vierling JM, Mantry P, et al. Randomized, double-blind, controlled study of glycerol phenylbutyrate in hepatic encephalopathy. Hepatology. 2014;59:1073–1083. doi: 10.1002/hep.26611.